Meridiano

Add Article

No Image Available

Article Details

Title

Article: Baidu, investors said to be in talks to raise US$2 billion for biotech start-up using AI technology

Impact Score

5 / 10

AI Summary (Processed Content)

Chinese tech giant Baidu is in discussions with investors to raise up to $2 billion for a biotech start-up. The start-up will focus on using artificial intelligence for drug discovery and disease diagnosis.

Baidu is not expected to be the controlling investor in this venture, according to sources. The fundraising effort reflects a broader trend of increased investment in the healthcare sector since the COVID-19 pandemic.

This trend has seen many tech companies expanding into digital health services, including online diagnosis and medicine delivery apps.

The main topics covered are Baidu's fundraising plans, the application of AI in biotechnology and healthcare, and the increased investment in the digital health sector post-pandemic.

Original URL

https://www.scmp.com/tech/science-research/article/3100934/baidu-investors-said-be-talks-raise-us2-billion-biotech-start?utm_source=rss_feed

Source Feed

Science & Research - South China Morning Post

Published Date

2020-09-10 01:30

Fetched Date

2026-03-04 14:32

Processed Date

2026-03-04 15:11

Embedding Status

Present

Cluster ID

Not Clustered

Raw Extracted Content

Advertisement
Baidu, investors said to be in talks to raise US$2 billion for biotech start-up using AI technology
- Baidu is raising money for a start-up that will use AI to discover new drugs and diagnose diseases, according to a source
- The plans come at a time of increased investment in the health care sector since the start of the Covid-19 pandemic
2-MIN READ2-MIN
Chinese tech giant Baidu is in talks with investors to raise up to US$2 billion over three years for a biotech start-up, which will use artificial intelligence (AI) technology to discover new drugs and diagnose diseases, a person with direct knowledge of the matter said.
A second person confirmed the start-up plan.
Baidu is unlikely to be the controlling investor, the first person said. Both sources spoke on condition of anonymity, adding they did not have more details on the investment as talks were still under way.
Advertisement
Baidu’s plans come at a time of increased investment in the health care sector since the outbreak of the Covid-19 pandemic, with many companies expanding into online diagnosis options to fill the gaps left by overstretched, overcrowded hospitals.
WeDoctor, backed by Tencent Holdings, Alibaba Group Holding’s health care arm and Ping An Good Doctor have joined the fray to develop apps that offer diagnosis, prescriptions, appointment bookings, 1-hour drug delivery and insurance.
(Alibaba is the parent company of the South China Morning Post.)
Advertisement
Select Voice
Select Speed
1.00x